In prostate cancer cells, inhibition of PLK1 with BI2536 significantly potentiated Paclitaxel-mediated cell death [38] while combination of BI2536 or BI6727 with histone deacetylases had antitumor effects in vitro [39]. Here, PLK1 is linked to prostate cancer.